PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21381981-3	2011	S/GSK1349572 represents a new INI in current development.	dolutegravir	2-12	PHD finger protein 5A	Homo sapiens	30-33	
25924475-5	2015	Comparing the two INIs as the "anchor" for HAART, DTG exhibited an equivalent CI to that of RAL on wild type HIV-1 replication; but a greater synergy than RAL on INI-resistant HIV-1 replication.	dolutegravir	50-53	PHD finger protein 5A	Homo sapiens	18-21	
29957545-1	2018	BACKGROUND: Dolutegravir (DTG) is a next-generation HIV integrase inhibitor (INI) with an increased genetic barrier to resistance with respect to raltegravir (RAL) or elvitegravir (EVG).	dolutegravir	12-24	PHD finger protein 5A	Homo sapiens	77-80	
29957545-1	2018	BACKGROUND: Dolutegravir (DTG) is a next-generation HIV integrase inhibitor (INI) with an increased genetic barrier to resistance with respect to raltegravir (RAL) or elvitegravir (EVG).	dolutegravir	26-29	PHD finger protein 5A	Homo sapiens	77-80	
25397500-0	2014	Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses.	dolutegravir	7-19	PHD finger protein 5A	Homo sapiens	27-30	
21381981-10	2011	EXPERT OPINION: S/GSK1349572 represents a new, unboosted, once-daily INI in development with distinct pharmacokinetics and resistance profile, which has showed promising potency and tolerability in the first clinical studies.	dolutegravir	18-28	PHD finger protein 5A	Homo sapiens	9-12	
22101373-11	2011	Global phase III clinical trials of dolutegravir (DTG), a second generation INI, are currently in progress.	dolutegravir	36-48	PHD finger protein 5A	Homo sapiens	76-79	
22101373-11	2011	Global phase III clinical trials of dolutegravir (DTG), a second generation INI, are currently in progress.	dolutegravir	50-53	PHD finger protein 5A	Homo sapiens	76-79